It’s always tough reading biased coverage, especially when reporters continue to slam collaboration between physicians and biopharmaceutical companies. I was particularly taken aback by Roni Caryn Rabin’s treatment of the issue in New York Times’ Well blog this week.
A recent article in Scientific American which explains “Why Doctors Prescribe Off-Label Drugs” caught my attention since non-approved use, also known as off-label use, of prescription medicines is often mentioned in the news without the context of why doctors choose to recommend it.
Can women really “have it all?” It is an age-old question that continues to generate significant societal interest and discussion.
Following our focus on young innovators this week, I’m reminded that ongoing research and innovation significantly improves the lives of patients and contributes to the health of our economy. The pace of innovation is staggering, and with so much information available at our fingertips, ensuring patients are utilizing reliable, accurate sources to make the best decisions for their health can be a challenge.
Nobody better represents the exciting science of our sector than those who are rolling up their sleeves and engaging in innovative biopharmaceutical research every day. As a result, we at PhRMA and our member companies are excited to highlight the stories and lives of some of our inspiring scientists. These individuals epitomize the passion, diversity, excitement, commitment and intellectual prowess of biopharmaceutical scientists. And they set an example for future generations of promising biopharma researchers.
Hurricane season is coming. It starts in less than a month. Now’s the time to get prepared. Here’s a clip from the Barometer Bob Show on the Weather Radio Broadcast Network. In this edition, Barometer Bob interviews RxResponse Executive Director Erin Mullen.
IMS’ latest report, Declining Medicine Use and Costs: For Better or Worse, reasserts the value that medicines provide in improving patients’ health and saving money on future health care costs. It’s also a great example of how and why the life cycle of medicines works so well.
Last week I wrote about my experience at the US Chamber’s Small Business Summit, and noted that I would be profiling some smaller businesses who work with pharmaceutical manufacturing companies as vendors.
As an industry, we need to do a better job of telling our story – who we are, what we believe in, and why the work we are doing is so important. If we don’t, we will continue to be misunderstood and the full value of innovative medicines may not be recognized.
In the (now famous) picture, a mumps-ridden Jeryl Hilleman screams at the camera while older sister Kristen cautiously holds the baby still enough to endure the prick of a needle held by their father, Merck vaccinologist Dr. Maurice Hilleman.
Blood cancers, such as leukemia and lymphoma, can affect anyone, including children. Each year, nearly 150,000 Americans are diagnosed with a blood cancer—accounting for about 9 percent of all new cancer diagnoses according to the American Cancer Society.
A recent article in the Telegram discussed translation medicine, a discipline that tries to reduce the gaps between discoveries made in the research laboratory and their application in clinical practice.
In a blog a couple of weeks ago, I summarized the many anti-chronic disease efforts PhRMA supports and explained why we’ve made those commitments. High on the list of programs we back is the Partnership to Fight Chronic Disease (PFCD) and a recent statement by the Centers for Disease Control and Prevention explains why:
Last week the CMS Office of the Actuary, following legislatively proscribed duties, stated that actual and projected Medicare expenditures for 2011 through 2015 are low enough that they will not trigger the Independent Payment Advisory Board (IPAB) to recommend binding cuts to the Medicare program.
PhRMA would like to congratulate Michael Froman, who today was nominated by President Obama to be the new United States Trade Representative. This position is critically-important as our nation strives to improve its standing in the global marketplace and create new, high-paying jobs that will propel our economy in the 21st Century. His extensive experience working on important economic issues will certainly benefit our nation as we look toward a trade policy that will build a foundation for future prosperity.
Not taking our medicines as prescribed is a serious problem and finding remedies to help patients stick with their treatments as directed would go a long way to better health, not to mention helping control healthcare costs.
It was suggested yesterday that drug companies aren’t putting enough resources into developing medicines for mental illness. This couldn’t be further from the truth. The reality is that as an industry, we are deeply vested in finding new treatments for patients suffering from debilitating neurological and mental health illnesses.